Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient;Epidemiología, diagnóstico y tratamiento de las infecciones fúngicas respiratorias en el paciente crítico

Revista Espanola de Quimioterapia

Volumn 26, Issue 2, 2013, Pages 173-188

  Garnacho Montero, José ^a   Olaechea, Pedro ^b   Alvarez Lerma, Francisco ^c   Alvarez Rocha, Luis ^d   Blanquer, José ^e   Galván, Beatriz ^f   Rodriguez, Alejandro ^g   Zaragoza, Rafael ^h   Aguado, José María ⁱ   Mensa, José ^j   Solé, Amparo ^k   Barberán, José ^l  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^h HOSPITAL UNIVERSITARIO DR PESET   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l UNIVERSIDAD SAN PABLO CEU   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; GALACTOMANNAN; STEROID; VORICONAZOLE;

ARTICLE; ASPERGILLUS; CANDIDA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CRITICALLY ILL PATIENT; FUNGAL COLONIZATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; LUNG ASPERGILLOSIS; LUNG MYCOSIS; NONHUMAN; PNEUMONIA; RESPIRATORY FAILURE; RISK FACTOR; SEPSIS; TREATMENT PLANNING; ZYGOMYCETES;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; BIOLOGICAL MARKERS; CANDIDIASIS; CRITICAL ILLNESS; HUMANS; LUNG DISEASES, FUNGAL; MUCORALES; MUCORMYCOSIS; MYCOSES; ORGAN TRANSPLANTATION; RESPIRATORY TRACT INFECTIONS; SPAIN;

EID: 84887953463     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (131)

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9.
2. Alvarez-Lerma F, Palomar M, León C, Olaechea P, Cerdá E, Bermejo B, et al. Colonización y/o infección por hongos en unidades de cuidados intensivos. Estudio multicéntrico de 1.562 pacientes. Med Clin (Barc) 2003; 121:161-6.
3. Estudio ENVIN. http://hws.vhebron.net/envin-helics/
4. Tortorano AM, Dho G, Prigitano A, Breda G, Grancini A, Emmi V, et al. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). Mycoses 2012; 55:73-9.
5. Smith JA, Kauffman CA. Pulmonary fungal infections. Respirology 2012; 17:913-26.
6. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009; 35:1526-31.
7. Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, et al. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 2006;129:110-7.
8. Segal BH. Aspergillosis. N Engl J Med 2009; 360:1870-84.
9. Latge JP. Aspergillus fumigatus and aspergillosis, Clin Microbiol Rev 1999; 12: 310-50.
10. Castón JJ, Linares MJ, Gallego C, Rivero A, Font P, Solís F, et al. Risk factors for pulmonary Aspergillus terreus infection in patients with positive culture for filamentous fungi. Chest 2007; 131:230-6.
11. Peláez T, Muñoz P, Guinea J, Valerio M, Giannella M, Klaassen CH, et al. Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit. Clin Infect Dis 2012; 54:e24-31.
12. Dutkiiewick R, Hage A. Aspergillus infections in the critically ill. Proc Am Thor Soc 2010;7:204-9.
13. Pemán J, Salavert M. Epidemiología general de la enfermedad fúngica invasora. Enferm Infecc Microbiol Clin 2012; 30:90-8.
14. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33:1824-33.
15. Bouza E, Guinea J, Peláez T, Pérez-Molina J, Alcalá L, Muñoz P. Workload due to Aspergillus fumigatus and significance of the organism in the microbiology laboratory of a general hospital. J Clin Microbiol 2005; 43:2075-9.
16. Graf K, Khani SM, Ott E, Mattner F, Gastmeier P, Sohr D, et al. Fiveyears surveillance of invasive aspergillosis in a university hospital. BMC Infect Dis 2011; 11:163.
17. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, León C, Alvarez-Lerma F, Nolla-Salas J et al. Isolation of Aspergillus spp. From the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome. Crit Care 2005; 9:R191-9.
18. Vandewoude KH, Blot SI, Depuydt P, Benoit D, Temmerman W, Colardyn F et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006; 10:R31
19. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004; 170:621-5.
20. Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp: implications for pathogenesis. Microbiology 1994; 140: 2475-9.
21. Hartemink KJ, Paul MA, Spijkstra JJ, Girbes AR, Polderman KH. Inmunoparalysis as a cause for invasive aspergilosis? Intensive Care Med 2003; 29: 2068-71.
22. Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J Clin Invest 1985; 76:1755-64.
23. Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2010; 16:870-7.
24. Xu H, Li L, Huang WJ, Wang LX, Li WF, Yuan WF. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect 2012; 18:403-8.
25. Fortún J, Meije Y, Fresco G, Moreno S. Aspergilosis. Formas clinicas y tratamiento. Enferm Infecc Microbiol Clin 2012; 30:201-8.
26. Fortún J, Martín-Dávila P, Moreno S, De Vicente E, Nuño J, Candelas A, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8:1065-70.
27. Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, Lumbreras C et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41:52-9.
28. Sole A, Morant P, Salavert M, Peman J, Morales P; Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11:359-365.
29. Marik PE. Fungal infections in solid organ transplantation. Expert Opin Pharmacother 2006; 7:297-305.
30. Solé A, Salavert M. Fungal infections after lung transplantation. Curr Opin Pulm Med 2009; 15:243-53.
31. Shahid H. Unique characteristics of fungal infections in lung transplant recipients. Clin Chest Med 2009; 30:307-313.
32. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (Suppl 1):S23-34.
33. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17:1859-67.
34. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-2.
35. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584-7.
36. Kontoyiannis DP, Reddy BT, Torres HA, Luna M, Lewis RE, Tarrand J et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 2002; 34:400-3.
37. Garnacho Montero J, Doblas A. Aspergilosis invasiva en el paciente crítico: Diagnóstico, planteamiento terapéutico y nuevas tendencias. Med Intensiva 2006; Supl 4: 38-46.
38. Routsi C, Kaltsas P, Bessis E, Rontogianni D, Kollias S, Roussos C. Airway obstruction and acute respiratory failure due to Aspergillus tracheobronchitis. Crit Care Med 2004; 32:580-582.
39. Parrón M, Torres I, Pardo M, Morales C, Navarro M, Martínez-Schmizcraft M. The halo sign in computed tomography images: differential diagnosis and correlation with pathology findings. Arch Bronconeumol 2008; 44:386-92.
40. Burghi G, Lemiale V, Seguin A, Lambert J, Lacroix C, Canet E et al. Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis. Intensive Care Med 2011; 37:1605-12.
41. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 2000; 31:188-9.
42. Fernández-Ruiz M, Silva JT, San-Juan R, de Dios B, García-Luján R, López-Medrano F et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 9:261-73.
43. Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, Van Lint MT et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38:913-6.
44. Cuenca-Estrella M. Diagnóstico de laboratorio de la enfermedad fúngica invasora. Enferm Infecc Microbiol Clin 2012; 30:257-64.
45. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-27.
46. He H, Ding L, Li F, Zhan Q. Clinical features of invasive bronchialpulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study. Crit Care 2011; 15:R5.
47. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121:448-57.
48. Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49:1688-93.
49. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177:27-34.
50. Acosta J, Catalan M, del Palacio-Peréz-Medel A, Lora D, Montejo JC, Cuetara MS et al. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1→ 3)-β-d-glucan chromogenic assay in serum samples. Clin Microbiol Infect 2011; 17:1053-60.
51. He H, Ding L, Sun B, Li F, Zhan Q. Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study. Crit Care 2012; 16:R138.
52. Clancy CJ, Jaber RA, Leather HL, Wingard JR, Staley B, Wheat LJ et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45:1759-65.
53. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M et al. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012; 54:633-43.
54. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005; 5:609-22.
55. Ayats J, Martín-Mazuelos E, Pemán J, Quindos G, Sanchez F, Garcia-Rodriguez J et al. Recomendaciones sobre el diagnóstico de la enfermedad fúngica invasora de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2010. Enferm Infecc Microbiol Clin 2011; 29:39-9.
56. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F et al. Multicenter clinical evaluation of the (1->3) beta-Dglucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-9.
57. Pazos C, Ponton J, Del Palacio A. Contribution of (1->3)-beta-Dglucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43:299-305.
58. De Vlieger G, Lagrou K, Maertens J, Verbeken E, Meersseman W, Van Wijngaerden E. Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study. J Clin Microbiol 2011; 49:3783-7.
59. Luong ML, Clancy CJ, Vadnerkar A, Kwak EJ, Silveira FP, Wissel MC et al. Comparison of an Aspergillus real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52:1218-26.
60. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9:89-96.
61. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52:1144-55.
62. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012; 54 (Suppl 1):S55-60.
63. Rello J, Esandi ME, Díaz E, Mariscal D, Gallego M, Vallès J. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998; 114:146-9.
64. el-Ebiary M, Torres A, Fàbregas N, de la Bellacasa JP, González J, Ramirez J et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 1997; 156:583-90.
65. Nseir S, Jozefowicz E, Cavestri B, Sendid B, Di Pompeo C, Dewavrin F et al. Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive Care Med 2007; 33:137-42.
66. Hamet M, Pavon A, Dalle F, Pechinot A, Prin S, Quenot JP et al. Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia. Intensive Care Med 2012; 38:1272-9.
67. Garnacho-Montero J, Díaz-Martín A, Cayuela-Dominguez A. Management of invasive Candida infections in non-neutropenic critically ill patients: from prophylaxis to early therapy. Int J Antimicrob Agents 2008; 32 (Suppl 2):S137-41.
68. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med 1996; 100:171-8.
69. Mortensen KL, Johansen HK, Fuursted K, Knudsen JD, Gahrn-Hansen B, Jensen RH et al. A prospective survey of Aspergillus spp. In respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis 2011; 30:1355-63.
70. Lucena P, Barberán J, Eroles G, Granizo JJ, Giménez MJ, Mir N et al. Significance of lower respiratory tract cultures yielding Aspergillus spp. growth in a hospital without transplant patients. Rev Esp Quimioter 2010; 23:190-5.
71. Khasawneh F, Mohamad T, Moughrabieh MK, Lai Z, Ager J, Soubani AO. Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome. J Crit Care 2006; 21:322-7.
72. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813-21.
73. Garnacho-Montero J, Amaya-Villar R. A validated clinical approach for the management of aspergillosis in critically ill patients: ready, steady, go! Crit Care 2006; 10:132.
74. Blot SI, Taccone FS, Van den Abeele AM, Bulpa P, Meersseman W, Brusselaers N et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012; 186:56-64.
75. Bulpa PA, Dive AM, Garrino MG, Delos MA, Gonzalez MR, Evrard PA et al. Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 2001; 27:59-67.
76. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30:782-800.
77. Ruiz-Camps I, Cuenca-Estrella M. Antifúngicos para uso sistémico. Enferm Infecc Microbiol Clin 2009; 27:353-62.
78. Lepak AJ, Andes DR. Antifungal PK/PD considerations in fungal pulmonary infections. Semin Respir Crit Care Med 2011; 32: 783-94.
79. Azanza Perea JR, Barberán J. Anfotericina B forma liposomica: un perfil farmacocinetico exclusivo. Una historia inacabada. Rev Esp Quimioter 2012; 25:17-24.
80. Ostrosky-Zeichner L, Man KA, Cohen SH. Amphotericin B: Time for a new "gold standard". Clin Infect Dis 2003; 37:415-25.
81. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 2009; 69:361-92.
82. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31:1155-63.
83. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 2008; 112: 1282-7.
84. Alvarez-Lerma F, Soriano MC, Rodríguez M, Catalán M, Llorente AM, Vidart N et al. Impacto de anfotericina B liposomal en la función renal en pacientes críticos con la función renal deteriorada. Rev Esp Quimioter 2012; 25:206-15.
85. Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009; 43:1647-57.
86. Garnacho Montero J, León Gil C, Almirante Gragera B, Álvarez Lerma F, Cuenca Estrella M, García Rodríguez JA et al. Recomendaciones terapéuticas en el paciente crítico no neutropénico. Med Intensiva 2005; Supl. 3: 43-52.
87. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35.
88. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Dellow E, Herbrecht R et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011; 54:e449-55.
89. Baddley JW, Stephens JM, Ji X, Gao X, Schlamm HT, Tarallo M. Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis 2013; 13:29.
90. Fortún J, Carratalá J, Gavaldá J, Lizasoain M, Salavert M, de la Cámara R et al. Recomendaciones sobre el tratamiento de la enfermedad fúngica invasiva por Aspergillus spp. y otros hongos filamentosos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2011. Enferm Infecc Microbiol Clin 2011; 29:435-54.
91. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-60.
92. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A et al. An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183:96-128.
93. Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45:205-16.
94. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
95. Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. Trials 2006; 7:3.
96. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
97. Jacobs F, Selleslag D, Aoun M, Sonet A, Gadisseur A. An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole. Eur J Clin Microbiol Infect Dis 2012; 31:1173-9.
98. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
99. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-11.
100. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 2009; 53:541-51.
101. Park WB, Kim NH, Kim KH, Lee SH, Nam WS, Yoon SH et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55:1080-7.
102. Hafner V, Czock D, Burhenne J, Riedel KD, Bommer J, Mikus G et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 2010; 54:2596-602.
103. Solís-Muñoz P, López JC, Bernal W, Willars C, Verma A, Heneghan MA et al. Voriconazole hepatotoxicity in severe liver dysfunction. J Infect 2013; 66:80-6.
104. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289-97.
105. Hachem RY, Boktour MR, Hanna HA, Husni RN, Torres HA, Afif C et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 2008; 112:1282-7.
106. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563-71.
107. Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64:1274-81.
108. Cornely OA, Vehreschild JJ, Vehreschild MJ, Würthwein G, Arenz D, Schwartz S et al. Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother 2011; 55:5798-803.
109. Marr KA, Baeck M, Carter RA, Kim HW, Grey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802.
110. Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006; 81:320-6.
111. Garbati MA, Alasmari FA, Al-Tannir MA, Tleyjeh IM. The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review. Int J Infect Dis 2012; 16:e76-81.
112. García-Gallo CL, García-Fadul C, Laporta-Hernández R, Ussetti-Gil P. Traqueobronquitis aspergilar en paciente sometido a trasplante pulmonar. Rev Iberoam Micol 2011; 28:129-33.
113. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47:503-9.
114. Kontoyiannis DP, Lewis R. How I treat mucormycosis. Blood 2011; 118:1216-24.
115. Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R et al. Diagnosis and treatment of mucormycosis in patients with haematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2012 Sep 14 [Epub ahead of print]
116. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010; 54:1298-304.
117. Garnacho-Montero J, Jiménez Parrilla F. Interacciones farmacológicas en el paciente crítico. ¿Un factor relevante para usar micafungina? Enferm Infecc Microbiol Clin 2011; 29 (Suppl 2):33-7.
118. Spellberg B, Fu Y, Edwards JE, Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49:830-2.
119. Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R et al. Combination polyene-caspofungin treatment of rhino-orbitalcerebral mucormycosis. Clin Infect Dis 2008; 47:364-71.
120. Monforte V, Ussetti P, López R, Gavaldà J, Bravo C, de Pablo A et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009; 28:170-5.
121. Monforte V, Ussetti P, Gavaldà J, Bravo C, Laporta R, Len O et al. Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 2010; 29:523-30.
122. Husain S, Capitano B, Corcoran T, Studer SM, Crespo M, Johnson B et al. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation 2010; 90:1215-9.
123. Borro JM, Solé A, de la Torre M, Pastor A, Fernandez R, Saura A et al. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40:3090-3.
124. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004; 77:232-7.
125. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17:1306-12.
126. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46:1401-8.
127. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011; 46:709-18.
128. Monforte V, López-Sánchez A, Zurbano F, Ussetti P, Solé A, Casals C et al. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant. J Heart Lung Transplant 2013; 32:313-9.
129. Hohlfeld JM, Tiryaki E, Hamm H, Hoymann HG, Krug N, Haverich A et al. Pulmonary surfactant activity is impaired in lung transplant recipients. Am J Respir Crit Care Med 1998; 158:706-12.
130. Le J, Schiller DS. Aerosolized delivery of antifungal agents. Curr Fungal Infect Rep 2010; 4:96-102.
131. Zaragoza R, Pemán J, Salavert M, Viudes A, Solé A, Jarque I et al. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?. Ther Clin Risk Manag 2008; 4:1261-80.